IP Library Granted Patent US 9,550,974
Granted Patent B2
US 9,550,974 · App. 14/154,163 · Granted Jan 24, 2017

Derivation of embryonic stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,550,974
App. No.
14/154,163
Granted
Jan 24, 2017
Kind
B2
Abstract

This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

Claims (12)

1. A method of producing a differentiated cell or tissue from a mammalian ES cell, the method comprising:

(a) culturing at least one isolated blastomere obtained from a mammalian embryo until a clump containing blastomere progeny cells forms;

(b) culturing the blastomere progeny cells for a suitable amount of time to obtain ES cells derived from the at least one isolated blastomere; and

(c) differentiating the ES cells into desired differentiated cells or tissues,

wherein the least one isolated blastomere of (a) and/or blastomere progeny cells of (a) and (b) are cultured in a medium comprising factors that inhibit differentiation.

2. The method of claim 1 , further comprising: (d) isolating the differentiated cells or tissues.

3. The method of claim 1 , wherein the differentiated cells or tissues are mesodermal, ectodermal, or endodermal cells or tissues.

4. The method of claim 2 , wherein the differentiated cells or tissues are mesodermal, ectodermal, or endodermal cells or tissues.

5. The method of claim 1 , wherein the differentiated cells or tissues are retinal pigment epithelial cells.

6. The method of claim 1 , wherein the differentiated cells or tissues are suitable for transplantation into a subject.

7. The method of claim 5 , wherein the differentiated cells or tissues are suitable for transplantation into a subject.

8. The method of claim 5 , wherein the retinal pigment epithelial cells are suitable for treatment of macular degeneration.

Assignments (3)
CHANGE OF NAME Recorded Jul 27, 2016
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 039493/0166 →
CHANGE OF NAME Recorded Jan 7, 2016
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 037459/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2014
From: LANZA, ROBERT; CHUNG, YOUNG
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 032156/0366 →